KR880009944A - Piperazine carboxylic acid, preparation method thereof and pharmaceutical composition containing the same - Google Patents

Piperazine carboxylic acid, preparation method thereof and pharmaceutical composition containing the same Download PDF

Info

Publication number
KR880009944A
KR880009944A KR1019880001680A KR880001680A KR880009944A KR 880009944 A KR880009944 A KR 880009944A KR 1019880001680 A KR1019880001680 A KR 1019880001680A KR 880001680 A KR880001680 A KR 880001680A KR 880009944 A KR880009944 A KR 880009944A
Authority
KR
South Korea
Prior art keywords
compound
formula
pharmaceutical composition
pharmaceutically acceptable
monohydrate
Prior art date
Application number
KR1019880001680A
Other languages
Korean (ko)
Other versions
KR960015190B1 (en
Inventor
하르트 애비셔 베른
Original Assignee
쟌 크라메르, 한스루돌프하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쟌 크라메르, 한스루돌프하우스, 산도즈 리미티드 filed Critical 쟌 크라메르, 한스루돌프하우스
Publication of KR880009944A publication Critical patent/KR880009944A/en
Application granted granted Critical
Publication of KR960015190B1 publication Critical patent/KR960015190B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음.No content.

Description

피페라진 카르복실산, 그의 제조방법 및 그를 함유하는 약학적 조성물Piperazine carboxylic acid, preparation method thereof and pharmaceutical composition containing the same

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (27)

하기식(II)의 화합물을 탈알킬화 하는 것으로 구성된 하기식(I)의 [R-(E)]-4-(3-포스포노-2-프로페닐)-2-피페라진 카르복실산 또는 그 염의 제조방법.[R- (E)]-4- (3-phosphono-2-propenyl) -2-piperazine carboxylic acid of formula (I) consisting of dealkylating a compound of formula (II): Preparation of Salts. 상기식에서 R은 (C1-4)알킬 또는 아릴(C1-4)알킬.Wherein R is (C 1-4 ) alkyl or aryl (C 1-4 ) alkyl. 상기 실시예에 서술되어진 바와같은 식(I)의 화합물 또는 그의 염의 제조방법.Process for preparing a compound of formula (I) or a salt thereof as described in the above examples. 제1항에 방법에 따라 제조된 상기 식(I)의 화합물 또는 그의 염.A compound of formula (I) or a salt thereof prepared according to the method of claim 1. 하기식(I)의 화합물 또는 그의 염.A compound of formula (I) or a salt thereof. 제4항에 있어서, 모노하이드레이트 또는 그의 염형의 화합물.The compound according to claim 4, which is monohydrate or a salt form thereof. 제4항 또는 제5항에 있어서, 약제로서 사용하기 위한 화합물 또는 약학적 허용 가능한 염.The compound or pharmaceutically acceptable salt according to claim 4 or 5 for use as a medicament. 제6항에 있어서, LH 분비의 장애에 치료하기 위한 화합물.The compound of claim 6 for treating a disorder of LH secretion. 제6항에 있어서, 증가된 근육강직에 치료하기 위한 화합물.The compound of claim 6 for treating increased muscle stiffness. 제6항에 있어서, 뇌의 허혈에 연관된 상태에 치료하기 위한 화합물.The compound of claim 6 for treating a condition associated with ischemia of the brain. 제6항에 있어서, 불안증에 치료하기 위한 화합물.The compound of claim 6 for treating anxiety. 제6항에 있어서, 정신분열에 치료하기 위한 화합물.The compound of claim 6 for treating schizophrenia. 제6항에 있어서, 우울증에 치료하기 위한 화합물.The compound of claim 6 for treating depression. 제6항에 있어서, CNS 장애에 치료하기 위한 화합물.The compound of claim 6 for treating a CNS disorder. 제6항에 있어서, 이명에 치료하기 위한 화합물.The compound of claim 6 for treating tinnitus. 제6항에 있어서, 간질에 치료하기 위한 화합물.The compound of claim 6 for treating epilepsy. 제6항에 있어서, 진통제로서 사용하기 위한 화합물.The compound of claim 6 for use as an analgesic. 제4항 또는 제5항의 화합물 또는 약학적으로 허용 가능한 그의 염과 약학적으로 허용 가능한 희석제 또는 담체로 구성된 약학적 조성물.A pharmaceutical composition comprising the compound of claim 4 or 5 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier. LH 분비와 연관된 장애에 사용하기 위한 약학적 조성물의 제조에 식(I) 화합물 또는 그의 모노하이드레이트 또는 약학적으로 허용 가능한 그의 염을 사용하는 방법.A method of using a compound of formula (I) or a monohydrate thereof or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for use in a disorder associated with LH secretion. 증가된 근육 강직에 사용하기 위한 약학적 조성물의 제조에 식(I) 화합물 또는 그의 모노하이드레이트 또는 약학적으로 허용 가능한 그의 염을 사용하는 방법.A method of using a compound of formula (I) or a monohydrate thereof or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition for use in increased muscle stiffness. 뇌의 허혈에 연관된 장애에 사용하기 위한 약학적 조성물의 제조에 식(I)화합물 또는 그의 모노하이드레이트 또는 약학적으로 허용 가능한 그의 염을 사용하는 방법.A method of using a compound of formula (I) or a monohydrate thereof or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition for use in a disorder associated with ischemia of the brain. 불안증의 치료에 사용하기 위한 약학적 조성물의 제조에 식(I)화합물 또는 그의 모노하이드레이트 또는 약학적으로 허용 가능한 그의 염을 사용하는 방법.A method of using the compound of formula (I) or monohydrate thereof or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for use in the treatment of anxiety. 정신분열증의 치료에 사용하기 위한 약학적 조성물의 제조에 식(I) 화합물 또는 그의 모노하이드레이트 또는 약학적으로 허용 가능한 그의 염을 사용하는 방법.A method of using a compound of formula (I) or a monohydrate thereof or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition for use in the treatment of schizophrenia. 우울증의 치료에 사용하기 위한 약학적 조성물의 제조에 식(I) 화합물 또는 그의 모노하이드레이트 또는 그의 모노하이드레이트 또는 약학적으로 허용 가능한 그의 염을 사용하는 방법.A method of using a compound of formula (I) or a monohydrate thereof or a monohydrate or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition for use in the treatment of depression. CNS 장애의 치료에 사용하기 위한 약학적 조성물의 제조에 (I) 화합물 또는 그의 모노하이드레이트 또는 약학적으로 허용 가능한 그의 염을 사용하는 방법.A method of using a compound (I) or a monohydrate thereof or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for use in the treatment of a CNS disorder. 이명의 치료에 사용하기 위한 약학적 조성물의 제조에 식(I) 화합물 또는 그의 모노하이드레이트 또는 약학적으로 허용 가능한 그의 염을 사용하는 방법.A method of using the compound of formula (I) or monohydrate thereof or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for use in the treatment of tinnitus. 간질의 치료에 사용하기 위한 약학적 조성물의 제조에 식(I) 화합물 또는 그의 모노하이드레이트 또는 약학적으로 허용 가능한 그의 염을 사용하는 방법.A method of using a compound of formula (I) or a monohydrate thereof or a pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for use in the treatment of epilepsy. 통증의 완화에 사용하기 위한 약학적 조성물의 제조에 식(I) 화합물 또는 그의 모노하이드레이트 또는 약학적으로 허용 가능한 그의 염을 사용하는 방법.A method of using a compound of formula (I) or a monohydrate thereof or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition for use in alleviating pain. ※참고사항:최초출원 내용에 의하여 공개하는 것임.※ Note: This is to be disclosed based on the first application.
KR1019880001680A 1987-02-18 1988-02-17 Piperazinecarboxylic acid, its preparation and pharmaceutical compositions containing it KR960015190B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8703749 1987-02-18
GB87037749 1987-02-18
GB878703749A GB8703749D0 (en) 1987-02-18 1987-02-18 Piperazinecarboxylic acid

Publications (2)

Publication Number Publication Date
KR880009944A true KR880009944A (en) 1988-10-06
KR960015190B1 KR960015190B1 (en) 1996-11-01

Family

ID=10612501

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880001680A KR960015190B1 (en) 1987-02-18 1988-02-17 Piperazinecarboxylic acid, its preparation and pharmaceutical compositions containing it

Country Status (28)

Country Link
JP (1) JPH0723387B2 (en)
KR (1) KR960015190B1 (en)
AT (1) AT391320B (en)
AU (1) AU613009B2 (en)
BE (1) BE1002427A3 (en)
CA (1) CA1327799C (en)
CH (1) CH675125A5 (en)
CY (1) CY1739A (en)
DE (1) DE3804936C2 (en)
DK (1) DK168441B1 (en)
ES (2) ES2011319A6 (en)
FI (1) FI86733C (en)
FR (1) FR2610932B1 (en)
GB (2) GB8703749D0 (en)
GR (1) GR1002471B (en)
HK (1) HK142093A (en)
HU (2) HU199858B (en)
IE (1) IE59098B1 (en)
IL (1) IL85436A0 (en)
IT (1) IT1219447B (en)
LU (1) LU87129A1 (en)
MY (1) MY103206A (en)
NL (1) NL8800412A (en)
NZ (1) NZ223529A (en)
PH (1) PH25512A (en)
PT (1) PT86776B (en)
SE (1) SE467256B (en)
ZA (1) ZA881146B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU202111B (en) * 1988-03-11 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing (r)-(e)-4--(3-phosphono-2-propenyl)-2-piperazine-carboxylic acid as active component
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
EP0488959A3 (en) * 1990-11-28 1992-08-05 Sandoz Ltd. New uses of competitive nmda receptor antagonists
US5260286A (en) * 1992-10-16 1993-11-09 Japan Tobacco, Inc. 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists
EP0826032A1 (en) * 1995-05-08 1998-03-04 Lonza Ag BIOTECHNICAL PRODUCTION PROCESS OF PIPERAZINE R-$g(a)-CARBOXYLIC ACIDS AND PIPERAZINE S-$g(a)-CARBOXYLIC ACID AMIDE
CZ298217B6 (en) 1997-05-12 2007-07-25 Ortho-Mcneil Pharmaceutical, Inc. Aryl substituted piperazine, intermediate for its preparation and pharmaceutical composition in which the aryl substituted piperazine is comprised
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
JP2008124531A (en) 2006-11-08 2008-05-29 Nec Electronics Corp Semiconductor device and audio processor chip
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1248531A (en) * 1984-04-17 1989-01-10 Jeffrey C. Watkins 4-substituted piperazine-2-carboxylic acids

Also Published As

Publication number Publication date
AT391320B (en) 1990-09-25
IT8847631A0 (en) 1988-02-12
PH25512A (en) 1991-07-24
DK168441B1 (en) 1994-03-28
NZ223529A (en) 1991-02-26
KR960015190B1 (en) 1996-11-01
FR2610932B1 (en) 1990-11-16
DK79688D0 (en) 1988-02-16
SE8800541A (en) 1988-08-19
FR2610932A1 (en) 1988-08-19
CY1739A (en) 1995-10-20
DK79688A (en) 1988-08-19
GR880100084A (en) 1988-12-16
GR1002471B (en) 1996-11-15
JPS63203691A (en) 1988-08-23
DE3804936C2 (en) 1997-02-13
GB2201676A (en) 1988-09-07
PT86776A (en) 1988-03-01
HK142093A (en) 1994-01-07
AU613009B2 (en) 1991-07-25
GB8803438D0 (en) 1988-03-16
ES2011319A6 (en) 1990-01-01
ATA36788A (en) 1990-03-15
SE8800541D0 (en) 1988-02-17
CH675125A5 (en) 1990-08-31
IE880413L (en) 1988-08-18
SE467256B (en) 1992-06-22
BE1002427A3 (en) 1991-02-05
IL85436A0 (en) 1988-07-31
IT1219447B (en) 1990-05-18
AU1175888A (en) 1988-08-25
NL8800412A (en) 1988-09-16
ES2021904A6 (en) 1991-11-16
IE59098B1 (en) 1994-01-12
DE3804936A1 (en) 1988-09-01
GB8703749D0 (en) 1987-03-25
MY103206A (en) 1993-05-29
FI86733C (en) 1992-10-12
PT86776B (en) 1992-05-29
ZA881146B (en) 1989-10-25
HU211269A9 (en) 1995-11-28
HUT49361A (en) 1989-09-28
GB2201676B (en) 1991-01-02
FI880744A0 (en) 1988-02-17
FI880744A (en) 1988-08-19
FI86733B (en) 1992-06-30
HU199858B (en) 1990-03-28
CA1327799C (en) 1994-03-15
IL85436A (en) 1992-12-01
JPH0723387B2 (en) 1995-03-15
LU87129A1 (en) 1988-09-20

Similar Documents

Publication Publication Date Title
GR3031492T3 (en) 1,4-Disubstituted piperazines for the treatment of disorders of the central nervous system and neuro-endocrine disorders
KR890701559A (en) 3-indolepyruvic acid derivatives and pharmaceutical uses thereof
KR880006193A (en) Piperidine Compounds and Their Preparation and Uses
KR850000462A (en) [[Bis (aryl) methylene] -1-piperidinyl] alkyl-pyrimidinone
KR950701223A (en) Anti-ichemic drugs
KR910015562A (en) Drugs for the treatment of brain failure diseases, novel 2- (1-piperazinyl) -4-phenylcycloalkano pyrimidine derivatives, and preparations thereof
KR880009944A (en) Piperazine carboxylic acid, preparation method thereof and pharmaceutical composition containing the same
KR910004599A (en) 1,3-dihydro-1- (pyridinylamino) -2H-indol-2-one, preparation method thereof and use thereof as a medicament
EP0133170A3 (en) A compound and a composition for therapeutic or diagnostic use and a method for therapeutic treatment
KR950005823A (en) 5-Amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative
KR890000417A (en) Thiourea derivatives
KR910004597A (en) 1- (pyridinylamino) -2-pyrrolidinone, preparation method thereof and use thereof as medicament
KR910000647A (en) Naphthylamino- and naphthyloxy-pyridineamine and related compounds, methods for their preparation and their use as dermatitis agents
KR890006621A (en) Anti-anxiety
KR890003378A (en) Naphthyridine Compounds Having Antimicrobial Activity Against Anaerobic Bacteria
KR880001596A (en) Dihydropyridine Compound-containing Brain Dysfunction
KR880007495A (en) 5-aryl-3H-1,2,4-triazol-3-one and their use in the treatment of neurodegenerative diseases
PT77982A (en) PROCESS FOR OBTAINING 6-SUBSTITUTED PYRIDAZINE AMINO DERIVATIVES ACTIVE ON THE CENTRAL NERVEUM SYSTEM
KR870006035A (en) Preparation of New Antibacterial 1-thienyl-4-oxoquinoline-3-carboxylic Acid Compound
ATE24834T1 (en) USE OF BETA-(1-ADAMANTYL)-ALPHA, ALPHADIMETHYLETHYLAMINE IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF EXTERNAL OTITIS IN DOGS.
KR870001153A (en) Pharmaceutical composition containing diphenoxyethylamine derivative and its production method
KR880001630A (en) 5-fluorouracil derivatives and uses thereof
ATE118773T1 (en) METHOD FOR PRODUCING 2-(3-PYRIDYL)-TETRAHYDROTHIOPYRAN-2-CARBONIC ACID THIOAMIDE-1-(1R,2R)OXIDES, THE SO OBTAINED 2-(3-PYRIDYL)-TETRAHYDROTHIOPYRAN-2-CARBOTHIOPYRAN-2-CARBOTHIOPYRAN-1-(1R,2R )OXIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
ATE56705T1 (en) PIPERIDE INDIVIDUALS, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
KR920011486A (en) Antitumor agents

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20011010

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee